<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03098433</url>
  </required_header>
  <id_info>
    <org_study_id>HM20005777</org_study_id>
    <nct_id>NCT03098433</nct_id>
  </id_info>
  <brief_title>Effects of Liothyronine on Energy Expenditure and Cardiovascular Function</brief_title>
  <official_title>Effects of Liothyronine on Energy Expenditure and Cardiovascular Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the short term effects of a single dose of liothyronine on the&#xD;
      cardiovascular system and energy expenditure&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 20, 2017</start_date>
  <completion_date type="Actual">June 24, 2019</completion_date>
  <primary_completion_date type="Actual">June 24, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>double blind, crossover</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>five hours</time_frame>
    <description>Cardiac output measured by Echocaridogram, Difference in Stroke Volume Pre- and Post- Drug Administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Energy Expenditure</measure>
    <time_frame>five hours</time_frame>
    <description>Energy expenditure measured by Whole-Room Indirect Calorimeter, Difference in energy Expenditure Pre- and Post- Drug Administration Kcal</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Liothyronine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant will receive a single dose of lithyronine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levothyroxine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each participant will receive a single dose of levothyroxine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each participant will receive a single dose of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liothyronine</intervention_name>
    <description>Single dose</description>
    <arm_group_label>Liothyronine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine</intervention_name>
    <description>Active comparator</description>
    <arm_group_label>Levothyroxine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI &gt;20&lt;30 kg/m2&#xD;
&#xD;
          -  TSH &gt;0.5&lt;5.0 mcIU/mL&#xD;
&#xD;
          -  Negative TPO antibodies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Use of prescription drugs&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Coronary artery disease&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  Anemia&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  Liver disease or ALT &gt;2.5 x the upper laboratory reference limit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco S Celi, MD, MHSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 7, 2017</study_first_submitted>
  <study_first_submitted_qc>March 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2017</study_first_posted>
  <results_first_submitted>February 2, 2021</results_first_submitted>
  <results_first_submitted_qc>March 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 26, 2021</results_first_posted>
  <disposition_first_submitted>July 7, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>March 2, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 26, 2021</disposition_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT03098433/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT03098433/Prot_SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Three Treatments in Random Order</title>
          <description>Each participant will receive a single dose of lithyronine, a single dose of levothyroxine, and a single dose of placebo, in a random order.&#xD;
Information on the order of treatments was not collected.&#xD;
Participants will attend three study visits. At the first study visit one of the three treatments will be randomly selected and administered.&#xD;
At the second study visit one of the remaining two treatments will be randomly selected and administered.&#xD;
At the third study visit the final treatment will be administered.&#xD;
The order of administration will not be analyzed therefore all participants are part of a single arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Three Treatments in Random Order</title>
          <description>Each participant will receive a single dose of lithyronine, a single dose of levothyroxine, and a single dose of placebo, in a random order.&#xD;
Information on the order of treatments was not collected.&#xD;
Participants will attend three study visits. At the first study visit one of the three treatments will be randomly selected and administered.&#xD;
At the second study visit one of the remaining two treatments will be randomly selected and administered.&#xD;
At the third study visit the final treatment will be administered.&#xD;
The order of administration will not be tracked.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.7" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cardiac Output</title>
        <description>Cardiac output measured by Echocaridogram, Difference in Stroke Volume Pre- and Post- Drug Administration</description>
        <time_frame>five hours</time_frame>
        <population>I participant did not undergo echocardiogram</population>
        <group_list>
          <group group_id="O1">
            <title>Three Treatments in Random Order</title>
            <description>Each participant will receive a single dose of lithyronine, a single dose of levothyroxine, and a single dose of placebo, in a random order&#xD;
Information on the order of treatments was not collected.&#xD;
Participants will attend three study visits. At the first study visit one of the three treatments will be randomly selected and administered.&#xD;
At the second study visit one of the remaining two treatments will be randomly selected and administered.&#xD;
At the third study visit the final treatment will be administered.&#xD;
The order of administration will not be tracked.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Output</title>
          <description>Cardiac output measured by Echocaridogram, Difference in Stroke Volume Pre- and Post- Drug Administration</description>
          <population>I participant did not undergo echocardiogram</population>
          <units>millilitres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Liothyronine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Levothyroxine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Energy Expenditure</title>
        <description>Energy expenditure measured by Whole-Room Indirect Calorimeter, Difference in energy Expenditure Pre- and Post- Drug Administration Kcal</description>
        <time_frame>five hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Three Treatments in Random Order</title>
            <description>Each participant will receive a single dose of lithyronine, a single dose of levothyroxine, and a single dose of placebo, in a random order.&#xD;
Information on the order of treatments was not collected.&#xD;
Participants will attend three study visits. At the first study visit one of the three treatments will be randomly selected and administered.&#xD;
At the second study visit one of the remaining two treatments will be randomly selected and administered.&#xD;
At the third study visit the final treatment will be administered.&#xD;
The order of administration will not be tracked.</description>
          </group>
        </group_list>
        <measure>
          <title>Energy Expenditure</title>
          <description>Energy expenditure measured by Whole-Room Indirect Calorimeter, Difference in energy Expenditure Pre- and Post- Drug Administration Kcal</description>
          <units>kcal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Liothyronine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.006" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Levothyroxine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.007" spread="0.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>20 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Three Treatments in Random Order</title>
          <description>Each participant will receive a single dose of lithyronine, a single dose of levothyroxine, and a single dose of placebo, in a random order.&#xD;
Information on the order of treatments was not collected.&#xD;
Participants will attend three study visits. At the first study visit one of the three treatments will be randomly selected and administered.&#xD;
At the second study visit one of the remaining two treatments will be randomly selected and administered.&#xD;
At the third study visit the final treatment will be administered.&#xD;
The order of administration will not be tracked.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Francesco S. Celi, MD, MHSc.</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804-828-9696</phone>
      <email>francesco.celi@vcuhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

